Clinical Trials on Non-small Cell Lung Cancer (NSCLC) in Hong Kong

Total 312 results

Dr Joanne CHIU

Recruiting

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

ALK Gene Rearrangement Positive | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Activating Mutation | Nsclc | ROS1 Gene Rearrangement | ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer

Hong Kong
The University of Hong Kong
Queen Elizabeth Hospital, Hong Kong; Prince of Wales Hospital, Shatin, Hong... and other collaborators

Active, not recruiting

Quest for Tumour Evolution of Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Hong Kong
The University of Hong Kong

Unknown

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

NSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB

Hong Kong
Nam Dinh University of Nursing
The Hong Kong Polytechnic University

Completed

Effect of Qigong on the Symptom Clusters of Dyspnea, Fatigue, and Anxiety.

Lung Cancer, Nonsmall Cell | Lung Cancer Non-Small Cell Stage 0 | Lung Cancer, Nonsmall Cell, Stage I | Lung Cancer Non-Small Cell Stage II | Lung Cancer, Limited Stage Small Cell

Hong Kong
AstraZeneca

Completed

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

Non-small Cell Lung Cancer

China
National Cancer Centre, Singapore
Pfizer

Active, not recruiting

Phase 2 Study of Dacomitinib in NSCLC

NSCLC Stage IV | NSCLC Stage IIIB | Recurrent NSCLC | NSCLC Stage IIIC | EGFR Positive Non-Small Cell Lung Cancer

Korea, Republic of, Hong Kong, Thailand, Singapore, Malaysia
Servier Bio-Innovation LLC
Regeneron Pharmaceuticals; Institut de Recherches Internationales Servier

Not yet recruiting

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)

Hong Kong, United States, Australia
Hong Kong Baptist University
The Queen Elizabeth Hospital

Terminated

Survey on Chinese Medicine Syndrome for Patients With Non Small Cell Lung Cancer

Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China
The University of Hong Kong

Not yet recruiting

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Non Small Cell Lung Cancer | Influenza Vaccine

China
The University of Hong Kong
Queen Mary Hospital, Hong Kong

Recruiting

Tai-Chi and Aerobic Exercise to Improve Emotional Symptom Cluster in Late-stage Lung Cancer Patients

Advanced Lung Non-Small Cell Carcinoma

Hong Kong
Galvanize Therapeutics, Inc.

Active, not recruiting

Feasibility Study of the Aliya System in the Treatment of Early Stage Non-small Cell Lung Cancer (INCITE ES)

Non Small Cell Lung Cancer

Hong Kong, Spain, Netherlands
National Cancer Centre, Singapore
Guardant Health AMEA, Inc.

Recruiting

Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

Non-small Cell Lung Cancer | ALK-Positive Lung Cancer

Korea, Republic of, Hong Kong, Malaysia, Singapore
Sanofi

Terminated

Docetaxel in Non Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Hong Kong
AbbVie

Available

Expanded Access to Telisotuzumab Vedotin

Non-Small Cell Lung Cancer (NSCLC)

Australia, Hong Kong, Israel, United States, Germany
National University Hospital, Singapore
AstraZeneca; Singapore Clinical Research Institute

Unknown

Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA (PLASMA)

Carcinoma, Non-Small-Cell Lung

Taiwan, Hong Kong, Thailand, Singapore, Korea, Republic of
Rain Oncology Inc

Terminated

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (RAIN)

NSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB Fusion

United States, Canada, Hong Kong
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations

Non-Squamous Non-Small Cell Lung Cancer

Hong Kong, Korea, Republic of, Taiwan, Thailand
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations (OSTARA)

Non-Small Cell Lung Cancer (NSCLC)

Korea, Republic of, Malaysia, Taiwan, Thailand, Hong Kong, Singapore, Canada
Novartis Pharmaceuticals

Active, not recruiting

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

EGFR-mutant Non-small Cell Lung Cancer

Taiwan, Germany, Canada, Italy, Singapore, Hong Kong
Astellas Pharma Inc

Completed

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

NSCLC | Non Small Cell Lung Cancer

United States, Canada, Korea, Republic of, Singapore, Thailand, Hong Kong
Eli Lilly and Company

Completed

A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

Taiwan, Korea, Republic of, Singapore, Thailand, Hong Kong
Novartis Pharmaceuticals

Active, not recruiting

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

ALK-positive NSCLC

Belgium, Spain, Italy, Australia, United States, Hong Kong, Canada, Singapore
Symphogen A/S

Completed

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

NSCLC | Non Small Cell Lung Cancer | Oncology | MET Gene Mutation | MET Gene Amplification

United States, Korea, Republic of, Denmark, Hong Kong, Taiwan, Spain
Cancer Therapeutics Research Group
National Cancer Institute (NCI)

Completed

3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer

Lung Cancer

Australia, Singapore, Hong Kong, Korea, Republic of
Takeda

Completed

A Chart Review Study of Adults With Advanced NSCLC (EXTRACT)

Non-small Cell Lung Cancer (NSCLC)

Hong Kong, France, Canada
Pfizer

Completed

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

NSCLC (Non-small Cell Lung Cancer)

Hong Kong, China, Taiwan, Malaysia, Thailand
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Non-small Cell Lung Cancer (NSCLC)

Japan, Germany, Spain, Italy, France, Thailand, Belgium, Netherlands, India, Malaysia, Taiwan, Australia, Canada, Czechia, Greece, Hong Kong
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

China, Hong Kong, Taiwan, Philippines, Thailand, Korea, Republic of, Indonesia
National Cancer Centre, Singapore
Singapore General Hospital

Recruiting

Molecular Profiling Project

Non-Small Cell Lung Cancer | Lung Cancer

Thailand, Singapore, Hong Kong, Brunei Darussalam, India, Malaysia
Hong Kong Children's Hospital
The University of Hong Kong

Recruiting

Propofol vs Sevo for Paediatric Tumor Surgery

Carcinoma | Cancer | Solid Tumor | Malignancy

Hong Kong
Novartis Pharmaceuticals

Terminated

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Advanced Non Small Cell Lung Cancer (NSCLC)

France, Italy, Taiwan, Spain, Netherlands, Japan, Hong Kong, Korea, Republic of, Norway, United States, United Kingdom, Poland
The University of Hong Kong
Janssen, LP

Unknown

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Follicular Lymphoma | Chronic Hepatitis B | Chronic Lymphocytic Leukemia | Mantle-Cell Lymphoma | Lymphoma, Small Lymphocytic | Indolent B-cell Lymphomas | Waldenstrom's Macroglobulinaemia

Hong Kong
Anaborex

Terminated

Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer

Anorexia | Carcinoma, Non-Small-Cell Lung | Weight Loss | Cachexia

China, Taiwan
Pfizer

Completed

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC

United States, Canada, Australia, Taiwan, Singapore, Japan, Korea, Republic of, Spain, Belgium, Switzerland, France, Germany, Hong Kong, Italy
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.

Non-Small Cell Lung Cancer

Hong Kong, Taiwan, Philippines, China, Thailand, Indonesia, Australia, Korea, Republic of
Merck KGaA, Darmstadt, Germany

Completed

Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) (FLEX)

Non Small Cell Lung Cancer (NSCLC)

Sweden, Australia, Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Turkey, United Kingdom, Germany, Poland, Ukraine, Argentina, Austria, Hungary, Netherlands, Slovakia, Taiwan, Chil... and more
Hoffmann-La Roche

Completed

A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC) (MERIT)

Non-Squamous Non-Small Cell Lung Cancer

Hong Kong, Spain, Russian Federation, France, Bulgaria, Germany, Estonia, Italy, Poland, Taiwan, United Kingdom, Singapore, Ireland, Belgium
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Non Small Cell Lung Cancer

United States, Israel, Taiwan, Korea, Republic of, Switzerland, Hong Kong
AstraZeneca

Completed

Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung Cancer (THASSOS-INTL)

Non-small Cell Lung Cancer

Turkey, Hong Kong, Australia, Egypt, India, Kuwait, United Arab Emirates
Novartis Pharmaceuticals

No longer available

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Non-small Cell Lung Cancer (NSCLC)

United States, Argentina, Korea, Republic of, Hong Kong, Thailand, Mexico, Jordan, Colombia, India, Philippines
Daiichi Sankyo

Recruiting

HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Spain, Japan, Netherlands, Taiwan
Bristol-Myers Squibb

Completed

Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer (CheckMate 078)

Non-Small Cell Lung Cancer

China, Hong Kong, Russian Federation, Singapore
Hoffmann-La Roche

Recruiting

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, China, Japan, Australia, Thailand, Slovakia, Argentina, Taiwan, Brazil, Hong Kong
Hoffmann-La Roche

Completed

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Spain, France, United Kingdom, Hong Kong
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Lung Cancer | Advanced or Metastatic Non-Small-Cell Lung Cancer | Resectable Non-Small-Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Hong Kong, Israel, United Kingdom
Eli Lilly and Company

Completed

A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer

Non-Small-Cell Lung Cancer

United Kingdom, Taiwan, Brazil, China, India, Korea, Republic of, Hong Kong
Takeda

Active, not recruiting

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

United States, Spain, France, Korea, Republic of, Hong Kong, Australia, Taiwan, United Kingdom, Canada, Turkey, Italy, China, Germany, Japan, Austria, Belgium, Greece, Israel, Netherlands, Portugal, Russian Federation, Singapore, Sw... and more
Cullinan Therapeutics Inc.

Recruiting

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (REZILIENT1)

Non Small Cell Lung Cancer | EGFR Exon 20 Mutation

United States, Taiwan, Spain, Korea, Republic of, Japan, Singapore, Italy, Netherlands, Hong Kong
Novartis Pharmaceuticals

Terminated

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Non-small Cell Lung Cancer

France, Spain, United States, Belgium, Netherlands, Canada, Italy, Singapore, Korea, Republic of, Czechia, Germany, Hong Kong
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Non-small Cell Lung Cancer (NSCLC)

China, Taiwan, United States, Australia, Israel, Hong Kong, Chile, Korea, Republic of, Canada, Malaysia, Thailand, Brazil

Clinical Trials on Non-small Cell Lung Cancer (NSCLC) in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations